Cargando…
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Personalized treatment of patients with advanced non-small-cell lung cancer based on clinical and molecular tumor features has entered clinical routine practice. The 2015 pathological classification of lung cancer mandates immunohistochemical and molecular analysis. Therapeutic strategies focused on...
Autores principales: | Pirker, Robert, Filipits, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821865/ https://www.ncbi.nlm.nih.gov/pubmed/26970967 http://dx.doi.org/10.1007/s10555-016-9612-6 |
Ejemplares similares
-
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019) -
EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020) -
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
por: Tiefenbacher, Andreas, et al.
Publicado: (2018) -
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018) -
Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
por: Pirker, Robert
Publicado: (2012)